Pelage Pharmaceuticals, Inc. is a biotechnology company developing novel drugs to promote hair health.


Currently, 400 million people, both men and women, suffer from Alopecia worldwide. There are only two FDA-approved medications for treating non-scarring Alopecia, Propecia and Rogaine (Minoxidil). Propecia is associated with adverse side effects and neither drug is very effective. More than $7 billion is being spent on hair loss treatments annually.


Pelage’s proprietary small molecules are the first to target hair follicle stem cell metabolism causing their activation.


  • Activates quiescent hair follicle stem cells
  • Small molecules access the hair follicles when applied to the scalp
  • No need for implants, injections or oral treatments


  • Pelage has licensed rights from the University of California to licensed patents covering the technology.

Development Stage:

  • Clinical

Select Publications: